European shares rose for the third straight session on Tuesday, building on a re...
FILE PHOTO: A share trader checks his screens at the stock exchange in Frankfurt, Germany October 2, 2017. REUTERS/Kai Pfaffenbach
Shares of the drugmaker rose 1.6%, lifting the healthcare sector .SXDP, after the company said its diabetes drug Farxiga met the main goal of the study for the treatment of patients with heart failure.outperforming. European markets have staged a comeback in the last two sessions on growing hopes that central banks and governments will step in to help global economies stave off a recession.
Investors will also keep an eye out for minutes from the latest policy meetings of both the Fed and the ECB later this week.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Stocks open sharply higher on trade and stimulus hopesU.S. stocks opened higher, putting key equity benchmarks on course for a third straight positive session, after reports that Germany was open to the use of...
Consulte Mais informação »
AstraZeneca's Farxiga passes late-stage heart failure testBritish drugmaker AstraZeneca said on Tuesday its diabetes drug Farxiga was succ...
Consulte Mais informação »
Being an African woman in tech as told by 3 Andela engineers“...defying all the odds stacked against them and excelling in this male dominated field.”
Consulte Mais informação »
Karissa Schweizer Swears By Old-School Spaghetti and Meatballs Before RacesThe 5K Bowerman Track Club runner shares the carb-rich diet that helps boost her performance during competition season.
Consulte Mais informação »
Equinor, Gazprom lose European gas market share as LNG surgesEurope's two biggest suppliers of pipeline gas, Norway's Equinor and R...
Consulte Mais informação »
Sarepta stock falls on FDA concerns about drugSarepta Therapeutics Inc. shares fell in the extended session Monday after the drug maker said the Food and Drug Administration raised concerns about its...
Consulte Mais informação »